Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.50 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.45 |
| ▸ | HTR6 | P50406 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27991335 | 0.81 | LMNA (0.54) | LMNARPS6KA3MAPTNPC1HPGD | |
| SCHEMBL30940215 | 0.78 | LMNA (0.67) | LMNAMAPTHPGDSMN1; SMN2HTR1A | |
| SCHEMBL4825861 | 0.78 | TDO2 (0.47) | LMNAMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4825848 | 0.78 | TDO2 (0.47) | LMNAMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL16231397 | 0.72 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11RPS6KA3 | |
| SCHEMBL29139424 | 0.72 | MAPK14 (0.44) | LMNAMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1554445 | 0.72 | MAPK14 (0.54) | LMNAMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL16230706 | 0.71 | MAPK14 (0.50) | LMNAMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL16225617 | 0.71 | MAPK14 (0.50) | LMNAMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3549781 | 0.70 | DCAF1 (0.52) | MAPK14MAPK13MAPK12MAPK11MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9475831-B2 | Formylpyrrole-based heterocycles for nucleic acid attachment to supports | ILLUMINA, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-20160137677-A1 | FORMYLPYRROLE-BASED HETEROCYCLES FOR NUCLEIC ACID ATTACHMENT TO SUPPORTS | ILLUMINA, INC. | 2016-05-19 | — | — | US | disclosed |
| US-9273074-B2 | Formylpyrrole-based heterocycles for nucleic acid attachment to supports | ILLUMINA, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150031833-A1 | FORMYLPYRROLE-BASED HETEROCYCLES FOR NUCLEIC ACID ATTACHMENT TO SUPPORTS | ILLUMINA, INC. | 2015-01-29 | — | — | US | disclosed |
| US-8883764-B1 | Formylpyrrole-based heterocycles for nucleic acid attachment to supports | ILLUMINA, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | MOMOSE YU | 2008-11-20 | — | — | US | disclosed |
| US-7423159-B2 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-09 | — | — | US | disclosed |
| CN-1731994-A | Prophylactic and therapeutic agent for neuropathy | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-02-08 | — | — | CN | disclosed |
| US-20060004069-A1 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1556032-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | Takeda Pharmaceutical Company Limited (JP) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004039365-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031833-A1 | FORMYLPYRROLE-BASED HETEROCYCLES FOR NUCLEIC ACID ATTACHMENT TO SUPPORTS | CCNY, FBL, NSUN2 | LMNA 316/4885MAPK14 4424/4885MAPK13 3865/4885 |
| US-20060004069-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | LMNA 2405/4885MAPK14 1479/4885MAPK13 1679/4885 |
| US-20160137677-A1 | FORMYLPYRROLE-BASED HETEROCYCLES FOR NUCLEIC ACID ATTACHMENT TO SUPPORTS | CCNY, FBL, NSUN2 | LMNA 316/4885MAPK14 4424/4885MAPK13 3865/4885 |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | LMNA 2405/4885MAPK14 1479/4885MAPK13 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.